Discover Myriad RBM’s Track to Success.
“Despite the known benefits of biomarkers in drug development, many biomarker discovery efforts fail because the patterns do not reproduce on a clinically validated platform. The Myriad RBM approach discovers new biomarker patterns on the same platform that will be used in clinical trials.”
DiscoveryMAP 175+ was designed in collaboration with our pharmaceutical and biotech customers and includes biomarkers known to be important in major disease indications. DiscoveryMAP 250+ includes over 70 additional analytes purportedly involved in cancer. Measuring over 250 analytes, these tests allow dynamic and simultaneous coverage of many physiologically relevant pathways. While producing the most data points per sample volume, Myriad RBM’s DiscoveryMAPs provide customers with robust, quantitative and cost-effective data.
Created by the founders of Luminex technology, these MAPs represent the culmination of 11 years of assay development and biomarker expertise. DiscoveryMAP 175+ and DiscoveryMAP 250+ help increase the odds of identifying novel protein biomarker patterns in drug development or diagnostic discovery projects. This data can support critical go/no-go decisions or identify candidate panels for potential companion diagnostics. Once a pattern is discovered, we can seamlessly convert those biomarkers into a CustomMAP for high volume sample processing resulting in better, more efficient clinical trials.
Myriad RBM Quality
DiscoveryMAP 175+ and DiscoveryMAP 250+ samples are tested on an automated platform in Myriad RBM’s CLIA-certified laboratory using proprietary reagents and software. Validation of Myriad RBM’s assays is guided by clinical laboratory standards and is designed to provide accurate and reproducible biomarker measurements. This enables the discovery of patterns made up of multiple biomarkers, many with small, yet reproducibly detectable changes. Multiplexing allows all of these assays to be performed using less than 750 microliters of serum or plasma, as compared to single-plex platforms, such as ELISA, which would require milliliters.
DiscoveryMAP analyte categories: